17 year old who has had resolved myocarditis after her 2nd dose of vaccine.; This is a spontaneous report received from a contactable reporter(s) (Physician) from medical information team.  A 17 year-old female patient received bnt162b2 (COMIRNATY) (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. Relevant medical history included: "myocarditis" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose), for COVID-19 Immunization.  The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious), outcome "unknown", described as "17 year old who has had resolved myocarditis after her 2nd dose of vaccine.".  Additional information: I have a 17 year old who had resolved myocarditis after her 2nd dose of vaccine. Mother wanted to know how and who can give the booster dose and when should it be given. Parents wanted to know what to do when she is eligible in 4 days. Relay the disclaimer that "Pfizer does not have any recommendations regarding the management of myocarditis and/or pericarditis in patients receiving Comirnaty. Clinical judgement based on the medical history and the clinical status of a specific patient should dictate the appropriate actions to be taken." The Interim Clinical Considerations state the following regarding "Myocarditis or pericarditis after receipt of a dose of an mRNA COVID-19 vaccine but before administration of a subsequent dose": It is unclear if people who developed myocarditis or pericarditis after a dose of an mRNA COVID-19 vaccine may be at increased risk of further adverse cardiac effects following a subsequent dose of the vaccine. Until additional safety data are available, experts recommend that people who develop myocarditis or pericarditis after a dose of an mRNA COVID-19 vaccine defer receiving a subsequent dose. Administration of a subsequent dose of an mRNA COVID-19 vaccine can be considered in certain circumstances for people who develop myocarditis or pericarditis after receiving a dose of an mRNA COVID-19 vaccine. Considerations for vaccination may include: Personal risk of severe acute COVID-19 (e.g., age, underlying conditions). Level of COVID-19 community transmission and personal risk of infection. Additional data on the risk of myocarditis or pericarditis following an occurrence of either condition after a dose of an mRNA COVID-19 vaccine. Additional data on the long-term outcomes of myocarditis or pericarditis that occurred after receipt of an mRNA COVID-19 vaccine. Timing of any immunomodulatory therapies; ACIP's general best practice guidelines for immunization can be consulted for more information. People who choose to receive a subsequent dose of an mRNA COVID-19 vaccine should wait atleast until their episode of myocarditis or pericarditis has completely resolved. This includes resolution of symptoms attributed to myocarditis or pericarditis, as well as no evidence of ongoing heart inflammation or sequelae as determined by the person's clinical team, which may include a cardiologist, and special testing to assess cardiac recovery. Decisions about proceeding with a subsequent dose should include a conversation between the patient, their parent, guardian, or caregiver (when relevant), and their clinical team. Clinicians should consult current clinical guidance for information on the evaluation and management of myocarditis.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.